Global Virtual Biopsy Market is valued at USD 0.8 Billion in 2024 and is predicted to reach USD 2.1 Billion by the year 2034 at a 12.3% CAGR during the forecast period for 2025 to 2034.
Virtual Biopsy Market Size, Share & Trends Analysis Report By Therapeutic Area (Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Endocrine Disorders, Gastrointestinal Disorders), Type Of Cancer, Type Of Imaging Technology, And End-user, By Region, And By Segment Forecasts, 2025 to 2034
A virtual biopsy is a non-invasive diagnostic method that offers a safer substitute for conventional tissue biopsy methods by examining tissue properties and identifying anomalies using cutting-edge imaging technology, such as MRI or CT scans, in conjunction with molecular analysis. Several factors are contributing to the significant rise of the virtual biopsy market. The necessity for early and precise diagnostic techniques has been brought to light by the rising incidence of cancer and other chronic illnesses. Furthermore, non-invasive techniques that provide less discomfort and faster recovery are becoming increasingly popular. Moreover, diagnostic accuracy has increased due to developments in imaging technology. Additionally, expanding healthcare spending and better infrastructure, particularly in emerging nations, are opening up access to virtual biopsy and fostering market growth in the coming years.
However, the high price of sophisticated diagnostic tools and technologies and the lack of trained professionals, which restricts accessibility, particularly in underdeveloped areas, are factors that may limit the growth of the target market during the forecast period. Furthermore, virtual biopsy techniques provide accurate, non-invasive diagnostics, and their use is growing among patients and healthcare professionals. Furthermore, early identification, treatment planning, and patient outcomes are improved when these technologies are incorporated into oncology research and clinical procedures, which is the global virtual biopsy market over the forecast period.
The virtual biopsy market is segmented based on therapeutic area, type of cancer, type of imaging technology, and end-user. Based on the therapeutic area, the market is segmented into oncological disorders, neurological disorders, cardiovascular disorders, ophthalmological disorders, endocrine disorders, gastrointestinal disorders, and others. By type of cancer, the market is segmented into solid malignancies, breast cancer, lung cancer, prostate cancer, colorectal cancer, brain cancer, and others. By type of imaging technology, the market is segmented into magnetic resonance imaging, computed tomography, X-ray, and ultrasound. The market is segmented by end-users into hospitals and clinics, research institutes, diagnostic centres, and others.
The oncological disorders category will hold a major share of the global virtual biopsy market in 2023. This is attributed to the increasing incidence of cancer and the need for non-invasive diagnostic methods. Additionally, unlike traditional invasive methods like tissue biopsies, virtual biopsy enables accurate tumour surveillance and early identification. Moreover, its widespread acceptance is fueled by the ability to quickly evaluate molecular and cellular data utilizing improved imaging and imaging-guided technologies, which provides substantial benefits in cancer diagnosis and therapy planning.
The breast cancer segment is projected to grow at a rapid rate in the global virtual biopsy market because breast cancer is becoming more commonplace globally, and there is a rising need for non-invasive diagnostic options. Virtual biopsy provides a quicker and less invasive alternative to traditional tissue biopsies by enabling precise cancer diagnosis and surveillance. Additionally, virtual biopsies can offer comprehensive insights into cancer features due to developments in imaging technologies and genetic analysis. Moreover, this is essential for early-stage breast cancer detection and individualized therapy planning, which supports market growth, especially in countries such as the US, Germany, the UK, China, and India.
The North American virtual biopsy market is expected to register the largest market share in terms of revenue shortly. This can be attributed to an extensive healthcare system, widespread use of cutting-edge diagnostic tools, and an increasing need for non-invasive cancer screening techniques. Leading biotechnology and healthcare firms are also present, contributing to the expansion of virtual biopsy solutions in the area. In addition, Asia Pacific is projected to grow rapidly in the global virtual biopsy market because of increasing awareness of non-invasive diagnostic techniques, rising cancer prevalence, and improved healthcare infrastructure. Furthermore, the region’s robust market expansion is also attributed to the adoption of cutting-edge medical technology and increasing healthcare investments in nations like China and India are also driving the region's growth.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 0.8 Billion |
| Revenue Forecast In 2034 | USD 2.1 Billion |
| Growth Rate CAGR | CAGR of 12.3% from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Mn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Therapeutic Area, Type Of Cancer, Type Of Imaging Technology, And End-user |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | GE Healthcare, Imaging Biometrics, OptoVibronex, ImageBiopsy Lab, Median Technologies, Quibim, Siemens Healthineers, City Imaging and Clinical Labs. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
By Type of Therapeutic Area-
By Type of Cancer-
By Type of Imaging Technology-
By End-User-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.